BridgeBio Pharma (BBIO) Cost of Revenue (2021 - 2026)
BridgeBio Pharma recorded quarterly Cost of Revenue of $9.9 million in Q1 2026, up 22.6% quarter-over-quarter from $8.1 million in Q4 2025, and up 276.62% year-over-year from $2.6 million in Q1 2025.
BridgeBio Pharma's Cost of Revenue history runs 6 years deep, the most recent figure standing at $9.9 million for Q1 2026.
- In Q1 2026, Cost of Revenue rose 276.62% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $28.3 million (up 377.48% YoY), while the FY2025 annual figure was $21.0 million, up 440.54% from the prior year.
- Cost of Revenue came in at $9.9 million for Q1 2026 at BridgeBio Pharma, up from $8.1 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $9.9 million in Q1 2026 to a low of $598000.0 in Q3 2023.
- A 5-year average of $2.5 million and a median of $675500.0 in 2022 frame the typical range for Cost of Revenue.
- Across the five-year window, Cost of Revenue slumped 58.28% in 2022 and surged 997.49% in 2025, its largest moves.
- BridgeBio Pharma's Cost of Revenue stood at $647000.0 in 2022, then slipped by 7.57% to $598000.0 in 2023, then surged by 248.49% to $2.1 million in 2024, then soared by 289.01% to $8.1 million in 2025, then advanced by 22.6% to $9.9 million in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $9.9 million, $8.1 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 207.52 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | 9.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.94 Mn |
| Mar 31, 2026 | 9.94 Mn |
| Dec 31, 2025 | 8.11 Mn |
| Dec 31, 2025 | 8.11 Mn |
| Sep 30, 2025 | 6.56 Mn |
| Sep 30, 2025 | 6.56 Mn |
| Jun 30, 2025 | 3.65 Mn |
| Jun 30, 2025 | 3.65 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Dec 31, 2024 | 2.08 Mn |
| Dec 31, 2024 | 2.08 Mn |
| Sep 30, 2024 | 598,000.00 |
| Sep 30, 2024 | 598,000.00 |
| Jun 30, 2024 | 598,000.00 |
| Jun 30, 2024 | 598,000.00 |
| Mar 31, 2024 | 598,000.00 |
| Mar 31, 2024 | 598,000.00 |
| Dec 31, 2023 | 598,000.00 |
| Dec 31, 2023 | 598,000.00 |
| Sep 30, 2023 | 598,000.00 |
| Sep 30, 2023 | 598,000.00 |
| Jun 30, 2023 | 599,000.00 |
| Jun 30, 2023 | 599,000.00 |
| Mar 31, 2023 | 651,000.00 |
| Mar 31, 2023 | 651,000.00 |
| Dec 31, 2022 | 647,000.00 |
| Dec 31, 2022 | 647,000.00 |
| Sep 30, 2022 | 739,000.00 |
| Sep 30, 2022 | 739,000.00 |
| Jun 30, 2022 | 700,000.00 |
| Jun 30, 2022 | 700,000.00 |
| Dec 31, 2021 | 1.55 Mn |
| Dec 31, 2021 | 1.55 Mn |
| Sep 30, 2021 | 1.45 Mn |
| Sep 30, 2021 | 1.45 Mn |
| Jun 30, 2021 | 109,000.00 |
| Jun 30, 2021 | 109,000.00 |